: Cyclooxygenases (COX) play a pivotal role in inflammation and are responsible for the production of prostaglandins (PGs). Two types of COXs have been identified as key biological targets for drug design: Constitutive COX-1 and inducible COX-2. Nonsteroidal anti-inflammatory drugs (NSAIDs) target COX-1, while selective COX-2 inhibitors are designed for COX-2. These COX isoforms are involved in multiple physiological and pathological pathways throughout the body. Overproduction of tumor necrosis factor-alpha (TNF-α) plays a role in COX-2's inflammatory activity. Tumor necrosis factor-alpha can contribute to cardiac fibrosis, heart failure, and various cancers by upregulating the COX-2/PGE2 axis. Therefore, suppressing COX activity has emerged as a potentially effective treatment for chronic inflammatory disorders and cancer. This review explores the mechanisms of TNF-α-induced COX-2/PGE2 expression, a significant pathophysiological feature of cancer development. Furthermore, we summarize chemical compounds with dual COX-2/TNF-α inhibitory actions, providing an overview of their structure-activity relationship. These insights may contribute to the development of new generations of dual-acting COX-2/TNF-α inhibitors with enhanced efficacy.
Introduction Identifying key differences between manufacturers’ submitted analysis and economic reanalysis by the Canadian Agency for Drugs and Technologies in Health (CADTH) is an important step toward understanding reimbursement recommendations. We compared economic values reported in manufacturers’ analysis with the CADTH reanalysis and also assessed methodological critiques. Methods Two reviewers extracted data from the clinical and economic reports in publicly available CADTH reports from 2018 to 2022. We used the Wilcoxon rank-sum test to assess the difference between mean economic values, and the Chi-square test to assess the association between the CADTH critique final recommendations. Results Of the total submissions, 99.4% included effectiveness critiques, 88.8% included model structure critiques, 69.1% included utility score critiques, and 78.7% included cost critiques. The median incremental cost-utility ratio (ICUR) in the manufacturers’ analyses was $138,658/quality-adjusted life-year (QALY), 2.5-fold lower than the CADTH’s reanalysis at $380,251/QALY (p < 0.001). The median CADTH reanalysis for 3-year budget impact analysis (BIA) was $4,575,102, which was 27% higher than the manufacturers’ submitted 3-year BIA (p < 0.001). CADTH requested a price reduction for 95% of all submissions, and the median price reduction request was 63.5%. In 2021 and 2022, the willingness-to-pay threshold identified in CADTH reports remained constant at $50,000 per QALY gained for all medications. Conclusion There was high frequency of CADTH critiques on manufacturers’ submissions in all four aspects of economic submissions: effectiveness, cost, utility score and structure. We observed a higher median incremental cost and lower median incremental QALYs in the CADTH reanalysis compared with the manufacturers’ submissions. The resulting higher ICUR in the CADTH reanalysis often leads to a recommendation that the manufacturer needs to reduce its price. The 3-year budget impact was higher in the CADTH reanalyses compared with manufacturers’ submissions.
25 October 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Background: Traumatic brain injury (TBI) frequently results in increased intracranial pressure (ICP), which may cause irreversible damage or fatality if not addressed. Prompt and precise detection of ICP is essential, particularly in emergency situations. Objectives: Ultrasonographic measurement of optic nerve sheath diameter (ONSD) has been suggested as a noninvasive technique for identifying ICP. This study seeks to evaluate the diagnostic accuracy of ONSD through ultrasonography in TBI patients. Methods: An umbrella review was performed in accordance with preferred reporting items for systematic reviews and meta‐analyses guidelines, concentrating on systematic reviews and meta‐analyses that detail diagnostic accuracy metrics for ONSD in TBI patients. Studies were incorporated if they provided data on sensitivity, specificity, or area under the curve (AUC) for ONSD in the detection of ICP. The AMSTAR 2 tool was used to figure out the risk of bias, and random‐effects models were used to put the results together. Results: The combined analysis of 41 incorporated studies, showed that the test was very accurate: it had a sensitivity of 0.89 (95% CI: 0.85–0.92), a specificity of 0.84 (95% CI: 0.80–0.89), and an AUC of 0.94 (95% CI: 0.91–0.95). The diagnostic odds ratio was 46 (95% CI: 26–81). Subgroup analyses demonstrated consistency among ONSD cut‐off values and ICP thresholds, notwithstanding significant heterogeneity. Conclusions: Ultrasonography measurement of ONSD shows that it is very accurate for finding high ICP in TBI patients. It offers a dependable, noninvasive screening instrument, especially in emergency contexts. Nevertheless, standardized measurement protocols and additional research are essential to enhance diagnostic thresholds.